General Information of Drug (ID: DM029TQ)

Drug Name
DS-1150b Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM029TQ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucose transporter type 4 (SLC2A4) TTP6MT5 GLUT4_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glucose transporter type 4 (SLC2A4) DTT SLC2A4 2.632 3.307 2.104 3.248
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Type-2 diabetes
ICD Disease Classification 5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucose transporter type 4 (SLC2A4) DTT SLC2A4 3.68E-01 -0.06 -0.73
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02004678) Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus. U.S. National Institutesof Health.
2 Sanford-Burnham goes fourth. SciBX 7(22); doi:10.1038/scibx.2014.633. June 5 2014